B-Lymphoblastic Leukemia / Lymphoma · line 2 · Inotuzumab ozogamicin for R/R Ph- B-ALL 2L+ (bridge to alloHCT)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-INOTUZUMAB-B-ALL |
| ID | IND-B-ALL-2L-INOTUZUMAB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-B-ALL |
| Sources | SRC-INOVATE-KANTARJIAN-2016 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for R/R Ph- B-ALL adult. Bridge-to-HCT intent dominant. Ukraine access barrier. Time-critical: relapse pathway must be confirmed within days.
Used By
Algorithms
ALGO-B-ALL-2L- ALGO-B-ALL-2L